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To the Editor,  
Chromosome deletions at 7q21.11 are rare, with few patients reported in the 
literature [Vergult et al 2015; Mazzaschi et al, 2013; Mefford et al, 2011].  Vergult et al 
[2015] reported three children with heterogenous 7q21 deletions who presented with 
epilepsy and apparent intellectual disability.  One of these patients had a translocation, 
the break points of which were said to disrupt the CACNA2D1 gene.  This suggested 
that CACNA2D1 is the likely candidate gene for the observed clinical features. 
Mazzaschi et al [2013] described a boy with apparent intellectual disability without 
epilepsy with a 7q21.11 deletion. Mefford et al [2011] reported a 3.9 Mb and 8.2 Mb 
deletion associated with epilepsy and intellectual disability. Here we report a further 
patient with the 7q21.11 deletion.  We also examined exome sequencing data from the 
Deciphering Developmental Disorders (DDD) project [Wight et al, 2015] in an attempt to 
identify pathogenic single nucleotide variants (SNVs) in genes from the 7q21.11 
deletion region in 4,293 children with developmental disorders. This is based on the 
hypothesis that deletion regions can be used to identify candidate genes for 
developmental disorders [Hempel et al, 2016].     
The proband was a six year old male who presented with autistic behavior and 
learning difficulties.  He was the second child of healthy, non-consanguineous parents.  
He was born at 37 weeks of gestation after an uncomplicated pregnancy.  There were 
no neonatal complications.  He had a history of global developmental delay.  He first 
walked at 24 months of age.  At the age of six years he could run but not use a tricycle.  
He first started to scribble at five years of age and could only use a spoon with difficulty 
by the age of six years.  At the age of six years he did not have recognizable words.  He 
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attended a special educational needs school.  He had no neurological symptoms of note 
and there was no history of seizures.  On examination his OFC was 52 cm (60th centile), 
height 107.5 cm (9th centile), and weight 16.35 kg (2nd centile).  He was non-
dysmorphic. His hands and feet were normal. Cardiovascular, respiratory and 
neurological examination were normal.  Magnetic resonance imaging of the brain was 
normal. The following tests were normal or negative: Fragile X, full blood count, liver 
function test, and urine and blood metabolic screens (glycosaminoglycans and organic 
and amino acids).  Written consent was obtained from the parents to give permission for 
publication of this report. This data in this report were considered to be part of routine 
clinical care and research approval was not required.   
Comparative genomic hybridization (OGT 60K v2.0 ISCA oligo array) 
demonstrated a 3.3 Mb deletion at 7q21.11 which included seven protein-coding genes. 
The breakpoints were reported as 7q21.1(79,622,282-82,919,619). Figure 1 illustrates 
the deletion in comparison to the previously reported patients.  Neither parent had the 
deletion.  No similar deletions were found in the recently published copy number variant 
(CNV) map of the human genome [Zarrei et al, 2015], which integrates CNV data from 
healthy individuals from multiple data sets such as the database of genomic variants.  
Trio exome sequencing data from 4,293 children in the DDD study was examined 
for plausible pathogenic SNVs in the seven protein coding genes found within the 
7q21.11 deletion region.  The methods of the DDD study have been described [Wight et 
al, 2015].  We could not identify any plausible pathogenic SNVs in any of these seven 
protein coding genes in children without a genomic diagnosis.  We defined plausible 
pathogenic SNVs as being de novo, having a minor allele frequency of <0.5% in the 
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Exome Aggregation Consortium database, and being predicted to be damaging by 
Polyphen or SIFT for missense variants or being predicted to be truncating (frameshift, 
nonsense).   
Here we report a further patient with a 7q21.11 deletion, demonstrating that this 
deletion can present with apparent intellectual disability without epilepsy.  We cannot 
exclude that the individual described here will develop epilepsy in the future, but the 
previously reported patients presented with epilepsy before the age of five years.  The 
individual we describe was non-dysmorphic.  However, two of the patients described by 
Vergult et al [2015] had facial dysmorphism, thus there may not be a consistent facial 
phenotype. Given the limited number of patients it is not possible to provide a definitive 
phenotypic description of the spectrum of clinical features associated with 7q21.11 
deletion.  However, apparent intellectual disability was consistent across all reported 
patients.  This deletion should be considered in the differential diagnosis of individuals 
presenting with both syndromic and non-syndromic intellectual disability. 
The mechanism by which 7q21.11 deletions cause epilepsy and apparent 
intellectual disability is unclear.  The smallest region of overlap between the published 
cases and the case described here contains three genes (HGF, CACNA2D1 and 
PCLO), implicating them in the pathogenesis.  Haploinsufficiency for one of these genes 
FRXOGXQGHUOLHWKHSDWLHQWV¶SKHQRW\SHIn an attempt to identify a single candidate gene 
for the 7q21.11 deletion syndrome we examined trio exome sequencing data from 4,293 
children with undiagnosed developmental disorders in the DDD study.  We could not 
identify any plausible pathogenic SNVs in the seven protein coding genes contained 
within the 7q21.11 deletion region in our case.  This is consistent with Mefford et al 
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[2011[ who did not identify any CACNA2D1 pathogenic SNVs in a series of 94 patients 
with epilepsy.  This suggests that haploinsufficiency for a single protein coding gene 
from the 7q21.11 region may not be responsible for the phenotype.  
As an alternative, it is possible that haploinsufficiency for a combination of protein 
coding genes results in the 7q21.11 deletion phenotype and it may be a true contiguous 
gene syndrome.  From the genes found within the smallest region of overlap, only 
CACNA2D1 and PCLO are expressed within the brain (data from gtex).  The PCLO 
gene encodes a pre-synaptic protein which plays a role in regulating neurotransmitter 
release.  Homozygous mutations in PCLO are associated with pontocerebellar 
hypoplasia type three [Maas et al, 2012].  Evidence from animal models suggests that 
PCLO plays a role in the formation and transport of pre-synaptic vesicles to the pre-
synaptic membrane [Geisler et al, 2015].  The CACNA2D1 gene encodes the 
alpha2delta1 subunit of the neuronal voltage gated calcium channel [Geisler et al, 
2015].  Neuronal calcium channels are found in both pre- and post-synaptic neuronal 
membranes and play a key role in synaptic signaling [Geisler et al, 2015].  It is possible 
that haploinsufficiency for both PCLO and CACNA2D1 might disrupt synaptic signaling 
and thus result in intellectual disability with or without epilepsy. 
In conclusion, we report an additional patient with the 7q21.11 deletion syndrome 
and provide evidence that haploinsufficiency for a single gene may not be the disease 
mechanism.  In vitro studies of the interaction between PCLO and CACNA2D1 will be 
required to examine the hypothesis that combined haploinsufficiency for these two 
synaptic proteins results in neuronal dysfunction. 
ACKNOWLEDGEMENTS 
Siddique et al  6 
 
 
The DDD study presents independent research commissioned by the Health Innovation 
Challenge Fund [grant number HICF-1009-003] see Nature 2015;519:223-8 
or www.ddduk.org/access.html for full acknowledgement. 
 
INTERNET RESOURCES 
GTEX: http://www.gtexportal.org/home/ 
Siddique et al  7 
 
 
 
REFERENCES 
Ahmed MY, Chioza BA, Rajab A, Schmitz-Abe K. l, Al-Khayat A, Al-Turki S, Baple EL, 
Patton MA, Al-Memar AY, Hurles ME, Partlow JN, Hills RS, Evrony GD, Servattalab 
S, Markianos K, Walsh CA, Crosby AH, Mochida GH. 2015.  Loss of PCLO function 
underlies pontocerebellar hypoplasia type 3.  Neurology 84: 1745-1750.   
Geisler S, Schopf CL, Obermair GJ. 2015.  Emerging evidence for specific neuronal 
functions of auxiliary calcium channel alpha2delta subunits.  Gen Physiol Biophys 
34: 105-118.  
Hempel A, Pagnamenta AT, Blyth M, Mansour S, McConnell V, Kou I, Ikegawa S, 
Tsurusaki Y, Matsumoto N, Lo-Castro A, Plessis G, Albrecht B, Battaglia A, Taylor 
JC, Howard MF, Keays D, Sohal AS, DDD Collaboration, Kuhl SJ, Kini U, McNeill A.  
2016. Deletions and de novo mutations of SOX11 are associated with 
neurodevelopmental disorders with features of Coffin-Siris syndrome.  J Med Genet 
53: 152-162.  
Maas C, Torres VI, Leal-Oritz S, Wagh D, Terry-Lorenzo RT, Fejtova A, Gundelfinger 
ED, Ziv NE, Garner CC. 2012. Formation of Golgi-derived active zone precursor 
vesicles. J Neurosci 32: 11095-11108.  
Mazzaschi RL, Ashton F, Aftimos S, George AM, Love DR. 2013.  Implications of a 
Chr7q21.11 microdeletion and the role of the PCLO gene in developmental delay. 
Sultan Qaboos Univ Med J 13: 306-310.  
Mefford HC, Yendle SC, Hsu C, Cook J, Geraghty E, McMahon JM, Eeg-Olofsson O, 
Sadleir LG, Gill D, Ben-Zeev B, Lerman-Sagie T, Mackay M, Freeman JL, 
Siddique et al  8 
 
 
Andermann E, Pelakanos JT, Andrews I, Wallace G, Eichler EE, Berkovic SF, 
Scheffer IE.  2011. Rare copy number variants are an important cause of epileptic 
encephalopathies. Ann Neurol 70: 974-985.  
Vergult S, Dheedene A, Meurs A, Faes F, Isidor B, Janssens S, Gautier A, Le Caignec 
C, Menten B. 2015. Genomic aberrations of the CACNA2D1 gene in three patients 
with epilepsy and intellectual disability. Eur J Hum Genet 23: 628 ± 632.  
Wight CF, Fitzgerald TW, Jones WD, Clayton S, McRae JF, van Kogelenberg M, King 
DA, Ambridge K, Barrett DM, Bayzetinova T, Bevan AP, Bragin E, Chatzimichali EA, 
Gribble S, Jones P, Krishnappa N, Mason LE, Miller R, Morley KI, Parthiban V, 
Prigmore E, Rajan D, Sifrim A, Swaminathan GJ, Tivey AR, Middleton A, Parker M, 
Carter NP, Barrett JC, Hurles ME, FitzPatrick DR, Firth HV; DDD stud l. 2015. 
Genetic diagnosis of developmental disorders in the DDD study: a scalable analysis 
of genome-wide research data. Lancet 385: 1305 ± 1314.   
Zarrei M, MacDonald JR, Merico D, Scherer SW. 2015. A copy number variation map of 
the human genome. Nat Rev Genet 16:172±83.  
 
 
 
 
  
Siddique et al  9 
 
 
FIGURE LEGENDS 
Figure 1.  Reported deletions at 7q21.11. Black horizontal bars represent deletions at 
7q21.11. The vertical dashed lines indicate the smallest region of overlap. This contains 
the HGF, CACNA2D1, and PCLO genes.  Only CACNA2D1 and PCLO are expressed 
in the brain.  The deletion labelled Vergult P2 extends into 7q21.12 to include the GRM3 
gene.  The deletion labeled Mefford P2 extends to 7q11.23 to include the TRIM74 and 
MAGI2 genes. 
